A carregar...
The role of targeted therapy in the management of patients with AML
Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulat...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5737125/ https://ncbi.nlm.nih.gov/pubmed/29296877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009829 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|